<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601080</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200077-516</org_study_id>
    <nct_id>NCT01601080</nct_id>
  </id_info>
  <brief_title>An Observational, Retrospective, UK &amp; Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device</brief_title>
  <acronym>READER</acronym>
  <official_title>REbiSmart™ Retrospective ADherencE Review (READER) An Observational, Retrospective, UK &amp; Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Limited, UK</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, retrospective, UK &amp; Ireland audit measuring patient adherence to
      Rebif® injections with the RebiSmart™ injection device. Data will be collected from Multiple
      Sclerosis (MS) patients who have been prescribed Rebif® and have been using the RebiSmart™
      device for injection for a minimum of 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage &quot;RebiSmart measured&quot; patient adherence to Rebif® injections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage &quot;RebiSmart measured&quot; patient adherence to Rebif® injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage &quot;RebiSmart™ measured&quot; patient adherence to Rebif® injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage &quot;RebiSmart™ measured&quot; patient adherence to Rebif® injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage &quot;RebiSmart™ measured&quot; patient adherence to Rebif® injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in patient adherence over time</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in percentage patient adherence between the first 12 months and second 12 months of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Possession Ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Difference of the patient MPR (as a percentage) versus the patient's RebiSmart™ recorded percentage adherence levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Possession Ratio</measure>
    <time_frame>24 months</time_frame>
    <description>Difference of the patient MPR (as a percentage) versus the patient's RebiSmart™ recorded percentage adherence levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence of patient subgroups</measure>
    <time_frame>12 months</time_frame>
    <description>&quot;RebiSmart™ measured&quot; percentage adherence within and between the following patient sub-groups:
patients who are and are not registered to MySupport (Rebif Support Programme)
patient age groups
patient gender
prior use of a DMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence of patient subgroups</measure>
    <time_frame>24 months</time_frame>
    <description>&quot;RebiSmart™ measured&quot; percentage adherence within and between the following patient sub-groups:
patients who are and are not registered to MySupport (Rebif Support Programme)
patient age groups
patient gender
prior use of a DMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence in the UK versus Ireland</measure>
    <time_frame>12 months</time_frame>
    <description>Reporting of UK and Ireland actual adherence levels separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence in the UK versus Ireland</measure>
    <time_frame>24 months</time_frame>
    <description>Reporting of UK and Ireland actual adherence levels separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Comfort Settings</measure>
    <time_frame>12 months</time_frame>
    <description>Preferred final comfort settings (at last injection)</description>
  </secondary_outcome>
  <enrollment type="Actual">230</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Relapsing Multiple Sclerosis who have been prescribed Rebif® (22mcg or 44mcg)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing Multiple Sclerosis (Relapsing Remitting Multiple Sclerosis and Secondary
             Progressive Multiple Sclerosis with relapses) according to the Association of British
             Neurologists criteria (30) in the UK and the revised 2005 McDonald criteria (31) in
             Ireland

          -  Prescribed Rebif® (22mcg or 44mcg) using the RebiSmart™ injection device

          -  Have been using RebiSmart™ for 24 months and be due a device replacement as part of
             their standard routine of care

          -  Registered with Bupa Home Healthcare (UK) or SENSE nurse (Ireland)

          -  Be willing to give consent for their adherence data to be captured in the audit

        Exclusion Criteria:

        Patients who do not fulfill entirely the inclusion criteria as well as the following:

          -  Discontinued Rebif before 24 months of treatment

          -  Unable or unwilling to give consent for their adherence data to be captured in the
             audit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Please contact the</name>
      <address>
        <city>Merck KGaA Communication Center for recruiting locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

